Cwm LLC Purchases 1,590 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Cwm LLC increased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 9.5% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,358 shares of the medical research company’s stock after purchasing an additional 1,590 shares during the period. Cwm LLC’s holdings in Thermo Fisher Scientific were worth $10,152,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Arkadios Wealth Advisors raised its stake in shares of Thermo Fisher Scientific by 4.1% during the 4th quarter. Arkadios Wealth Advisors now owns 933 shares of the medical research company’s stock worth $495,000 after purchasing an additional 37 shares during the period. Allworth Financial LP lifted its position in Thermo Fisher Scientific by 16.4% in the fourth quarter. Allworth Financial LP now owns 2,729 shares of the medical research company’s stock valued at $1,448,000 after purchasing an additional 385 shares during the last quarter. Equitable Trust Co. increased its stake in shares of Thermo Fisher Scientific by 21.0% during the fourth quarter. Equitable Trust Co. now owns 4,334 shares of the medical research company’s stock valued at $2,300,000 after buying an additional 751 shares during the period. BSW Wealth Partners increased its stake in shares of Thermo Fisher Scientific by 1.9% during the fourth quarter. BSW Wealth Partners now owns 1,231 shares of the medical research company’s stock valued at $654,000 after buying an additional 23 shares during the period. Finally, FARMERS & MERCHANTS TRUST Co OF LONG BEACH grew its stake in Thermo Fisher Scientific by 21.2% in the fourth quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 944 shares of the medical research company’s stock worth $501,000 after purchasing an additional 165 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Trading Up 1.9 %

Shares of TMO stock traded up $11.29 on Thursday, reaching $598.66. 231,241 shares of the company’s stock were exchanged, compared to its average volume of 1,559,617. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $622.30. The company’s fifty day simple moving average is $566.79 and its 200 day simple moving average is $569.32. The stock has a market capitalization of $228.52 billion, a PE ratio of 37.68, a P/E/G ratio of 2.87 and a beta of 0.77. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share for the quarter, topping the consensus estimate of $5.13 by $0.24. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The firm had revenue of $10.54 billion for the quarter, compared to the consensus estimate of $10.50 billion. During the same period in the previous year, the business earned $5.15 EPS. The firm’s revenue for the quarter was down 1.4% on a year-over-year basis. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 21.71 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Friday, September 13th will be paid a dividend of $0.39 per share. The ex-dividend date of this dividend is Friday, September 13th. This represents a $1.56 annualized dividend and a yield of 0.26%. Thermo Fisher Scientific’s payout ratio is presently 10.01%.

Analyst Ratings Changes

TMO has been the topic of a number of recent research reports. Raymond James increased their target price on Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th. Evercore ISI lowered their price target on Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. Barclays lowered their price target on Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating on the stock in a report on Friday, June 28th. Deutsche Bank Aktiengesellschaft upped their price target on Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a report on Thursday, April 25th. Finally, TD Cowen upped their price target on Thermo Fisher Scientific from $648.00 to $658.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Five investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average price target of $618.94.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $600.85, for a total value of $1,201,700.00. Following the completion of the transaction, the senior vice president now owns 13,083 shares of the company’s stock, valued at approximately $7,860,920.55. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 860 shares of the business’s stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $611.03, for a total transaction of $525,485.80. Following the completion of the sale, the chief accounting officer now directly owns 1,814 shares in the company, valued at approximately $1,108,408.42. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $600.85, for a total value of $1,201,700.00. Following the sale, the senior vice president now owns 13,083 shares of the company’s stock, valued at $7,860,920.55. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 33,084 shares of company stock worth $19,767,092. 0.34% of the stock is currently owned by insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.